Despite this, the treatment of acute promyelocytic leukemia (APL) represents a prime example of a drug combination that targets both differentiation blockade and the self-renewal activity of LSCs through the proteasome-dependent degradation of the PML-RARα fusion protein, as described in the pioneer work from de The and colleagues [211,212]. This evidence concerns the gene RARA and acute promyelocytic leukemia.